Praxis Precision Medicines (PRAX) Cash from Financing Activities (2019 - 2026)
Praxis Precision Medicines (PRAX) posted quarterly Cash from Financing Activities of $609.4 million for Q1 2026, up 1022.98% year-over-year from $54.3 million in Q1 2025, and down 0.5% quarter-over-quarter from $612.5 million in Q4 2025.
Praxis Precision Medicines (PRAX) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Praxis Precision Medicines' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $609.4 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 1022.98% year-over-year to $609.4 million; the TTM figure through Mar 2026 stood at $1.3 billion (up 225.87% YoY), while the FY2025 annual figure was $702.2 million, up 36.52% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $609.4 million, down from $612.5 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $612.5 million in Q4 2025, with the low at $504000.0 in Q2 2022.
- The 5-year median for Cash from Financing Activities is $23.3 million (2023), against an average of $120.5 million.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities slumped 99.49% in 2022, then surged 13724.4% in 2023.
- Praxis Precision Medicines' Cash from Financing Activities stood at $5.4 million in 2022, then fell by 23.41% to $4.1 million in 2023, then soared by 2657.32% to $113.8 million in 2024, then jumped by 438.4% to $612.5 million in 2025, then declined by 0.5% to $609.4 million in 2026.
- Business Quant data shows PRAX's Cash from Financing Activities at $609.4 million in Q1 2026, $612.5 million in Q4 2025, and $6.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Praxis Precision Medicines | 10.24 Bn | 9.48 Bn | - | 4.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.57 Mn |
| Jun 30, 2026 | 4.57 Mn |
| Mar 31, 2026 | 609.43 Mn |
| Mar 31, 2026 | 609.43 Mn |
| Dec 31, 2025 | 612.52 Mn |
| Dec 31, 2025 | 612.52 Mn |
| Sep 30, 2025 | 6.76 Mn |
| Sep 30, 2025 | 6.76 Mn |
| Jun 30, 2025 | 28.63 Mn |
| Jun 30, 2025 | 28.63 Mn |
| Mar 31, 2025 | 54.27 Mn |
| Mar 31, 2025 | 54.27 Mn |
| Dec 31, 2024 | 113.77 Mn |
| Dec 31, 2024 | 113.77 Mn |
| Sep 30, 2024 | 1.44 Mn |
| Sep 30, 2024 | 1.44 Mn |
| Jun 30, 2024 | 216.36 Mn |
| Jun 30, 2024 | 216.36 Mn |
| Mar 31, 2024 | 182.76 Mn |
| Mar 31, 2024 | 182.76 Mn |